Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Xoma Xanelim

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Results of a second Phase III Xanelim trial, presented July 30 at the American Academy of Dermatology meeting, show that 22% of patients receiving 1 mg/kg Xanelim and 28% of patients given 2 mg/kg once weekly achieved the study's primary endpoint of a 75% or greater improvement in the Psoriasis Area Severity Index score after 12 weeks treatment vs. 5% of placebo patients. The trial enrolled 597 patients with moderate to severe plaque psoriasis. A second 12-week course of treatment in 134 partial responders resulted in a 75% or greater improvement in PASI score for 58% of patients receiving Xanelim 2 mg/kg weekly and 29% for those receiving 2 mg/kg every other week vs. 4% for placebo. Genentech aims "ultimately to position [efalizumab] for chronic and/or maintenance therapy" of psoriasis, Genentech Product Development Head Bernice Welles, MD, said during a July 31 conference call. Results of the firm's first pivotal trial were presented June 21 (Pharmaceutical Approvals Monthly, July 2001, p. 21)

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Topics

UsernamePublicRestriction

Register

PS001564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel